Role of proteasomes in T cell activation and proliferation

Journal of Immunology

Volumn 160, Issue 2, 1998, Pages 788-801

  Wang, Xin ^a   Luo, Hongyu ^a   Chen, Huifang ^a   Duguid, William ^c   Wu, Jiangping ^a,b,d  

^a Louis Charles Simard Research Center   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN E; PROTEASOME; PROTEINASE INHIBITOR;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE ACTIVATION;

ACETYLCYSTEINE; APOPTOSIS; B-LYMPHOCYTES; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; G1 PHASE; HUMANS; INTERPHASE; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICROTUBULE-ASSOCIATED PROTEINS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, INTERLEUKIN-2; S PHASE; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0031985626     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Jentsch, S., and S. Schlender. 1995. Selective protein degradation: a journey's end within the proteasome. Cell 82:881.
2. Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79: 13.
3. Orlowski, M., and S. Wilk. 1981. A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides. Biochem. Biophys. Res. Commun. 101:814.
4. Wilk, S., and M. Orlowski. 1983. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. 40:842.
5. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761.
6. Deshaies, R. J., V. Chau, and M. Kirschner. 1995. Ubiquitination of the G1 cyclin Cln2p by a Cdc34p-dependent pathway. EMBO J. 14:303.
7. Cdc28-mediated control of Cln3 cyclin degradation. Mol. Cell. Biol. 15:731.
8. Salama, S. R., K. B. Hendricks, and J. Thorner. 1994. G1 cyclin degradation: the PEST motif of yeast Cln2 is necessary, but not sufficient, for rapid protein turnover. Mol. Cell. Biol. 14:7953.
9. Seufert, W., B. Futcher, and S. Jentsch. 1995. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. Nature 373:78.
10. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495.
11. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682.
12. Palombella, V. J., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773.
13. Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787.
14. Groettrup, M., A. Soza, U. Kuckelkorn, and P. M. Kloetzel. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol. Today 17:429.
15. Peters, J. M. 1994. Proteasomes: protein degradation machines of the cell. Trends Biochem. Sci. 19:377.
16. Realini, C., W. Dubiel, G. Pratt, K. Ferrell, and M. Rechsteiner. 1994. Molecular cloning and expression of a γ-interferon-inducible activator of the multicatalytic protease. J. Biol. Chem. 269:20727.
17. Ahn, J. Y., N. Tanahashi, K. Akiyama, H. Hisamatsu, C. Noda, K. Tanaka, C. H. Chung, N. Shibmara, P. J. Willy, J. D. Mott, C. A. Slaughter, and G. N. DeMartino. 1995. Primary structures of two homologous subunits of PA28, a γ-interferon-inducible protein activator of the 20S proteasome. FEBS Letters, 366:37.
18. Groettrup, M., A. Soza, M. Eggers, L. Kuehn, T. P. Dick, H. Schild, H. G. Rammensee, U. H. Koszinowski, and P. M. Kloetzel. 1996. A role for the proteasome regulator PA28 α in antigen presentation. Nature 381:166.
19. Wang, X., S. Omura, L. I. Szweda, Y. Yang, J. Berard, J. Seminaro, and J. Wu. 1997. Rapamycin inhibits proteasome activator expression and proteasome activity. Eur. J. Immunol. 27:2781.
20. Vinitsky, A., C. Michaud, J. C. Powers, and M. Orlowski. 1992. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31:9421.
21. Tsubuki, S., H. Kawasaki, Y. Saito, N. Miyashita, M. Inomata, and S. Kawashima. 1993. Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochem. Biophys. Res. Commun. 196:1195.
22. Sasaki, T., M. Kishi, M. Saito, T. Tanaka, N. Higuchi, E. Kominami, N. Katunuma, and T. Murachi. 1990. Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J. Enzyme Inhib. 3:195.
23. Omura, S., T. Fujimoto, K. Otoguro, K. Matsuzaki, R. Moriguchi, H. Tanaka, and Y. Sasaki. 1991. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. 44:113.
24. Omura, S., K. Matsuzaki, T. Fujimoto, K. Kosuge, T. Furuya, S. Fijita, and A. Nakagawa. 1991. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot. 44:117.
25. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:72.
26. June, C. H., J. A. Ledbetter, P. S. Linsley, and C. B. Thompson. 1990. Role of the CD28 receptor in T-cell activation. Immunol. Today 11:211.
27. Luo, H., H. Chen, P. Daloze, J. Y. Chang, G. St-Louis, and J. Wu. 1992. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 53: 1071.
28. Luo, H., H. Chen, P. Daloze, G. St-Louis, and J. Wu. 1993. Anti-CD28 antibody-and IL-4-induced human T cell proliferation is sensitive to rapamycin. Clin. Exp. Immunol. 94:371.
29. Liu, X., H. Zou, C. Slaughter, and X. Wang. 1997. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175.
30. Tsao, M. S., and M. P. Duguid. 1987. Establishment of propagatable epithelial cell lines from normal adult rat pancreas. Exp. Cell Res. 168:365.
31. Shan, X., H. Luo, B. Houle, and J. Wu. 1994. Expression of a G-protein β subunit-related gene during lymphocyte activation. Int. Immunol. 6:739.
32. d-specific TCR transgenic mice transplanted with allogenic hearts under the cover of a short-term rapamycin treatment. J. Immunol. 157:4297.
33. Brown, E. J., and S. L. Schreiber. 1996. A signaling pathway to translational control. Cell 86:517.
34. Tam, S. W., A. M. Theodoras, J. W. Shay, G. F. Draetta, and M. Pagano. 1994. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene 9:2663.
35. Lukas, J., J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, and J. Bartek. 1995. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125.
36. Van der Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050.
37. Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73:1059.
38. Pagano, M., R. Pepperkok, F. Verde, W. Ansorge, and G. Draetta. 1992. Cyclin A is required at two points in the human cell cycle. EMBO J. 11:961.
39. Hall, M., S. Bates, and G. Peters. 1995. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581.
40. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817.
41. Kip1 accumulation during the cell cycle. Science 271:1861.
42. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570.
43. Dick, L. R., A. A. Cruikshank, L. Grenier, F. D. Melandri, S. L. Nunes, and R. L. Stein. 1996. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J. Biol. Chem. 271: 7273.
44. Grimm, L. M., A. L. Goldberg, G. G. Poirier, L. M. Schwartz, and B. A. Osborne. 1996. Proteasomes play an essential role in thymocyte apoptosis. EMBO J. 15: 3835.
45. Sadoul, R., P.-A. Fernandez, A.-L. Quiquerez, I. Martinou, M. Maki, M. Schroter, J. D. Becherer, M. Irmler, J. Tschopp, and J.-C. Martinou. 1996. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15:3845.
46. Imajoh-Ohmi, S., T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura, and H. Kikuchi. 1995. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun. 217:1077.
47. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682.
48. Glotzer, M., A. Murray, and M. Kirschner. 1991. Cyclin is degraded by the ubiquitin pathway. Nature 349:132.
49. Xiong, Y., H. Zhang, and D. Beach. 1992. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505.
50. Tsai, L. H., T. Takahashi, V. S. Caviness, Jr., and E. Harlow. 1993. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119:1029.
51. Won, K. A., and S. I. Reed. 1996. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15:4182.
52. Guadagno, T. J., M. Obtsubo, J. M. Roberts, and R. K. Assoian. 1993. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262:1572.
53. Ink4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257.
54. Ink4. Cancer Res. 54:5816.
55. Hirai, H., and C. J. Sherr. 1996. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol. Cell. Biol. 16:6457.
56. Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551.
57. Firpo, E. J., A. Koff, M. J. Solomon, and J. M. Roberts. 1994. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol. 14:4889.
58. Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487.
59. Morice, W. G., G. Wiederrecht, G. J. Brunn, J. J. Siekierka, and R. T. Abraham. 1993. Rapamycin inhibition of interleukin-2-dependent p33 (CDK2) and p34 (CDC2) kinase activation in T lymphocytes. J. Biol. Chem. 268:22737.
60. Cip1. Nature 375:159.
61. Waga, S., and B. Stillman. 1994. Anatomy of a DNA replication fork revealed by reconstitution of SV40 DNA replication in vitro. Nature 369:207.
62. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750.
63. cip-1 in the maintenance of stem/ progenitor cells in vivo. Blood 88:3710.
64. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847.
65. Costello, R., C. Cerdan, C. Lipcey, M. Algarte, Y. Martin, P. A. Baeuerle, D. Olive, and J. Imbert. 1993. The role of NF-kappa B1 (p50/p105) gene expression in activation of human blood T-lymphocytes via CD2 and CD28 adhesion molecules. Cell Growth Differ. 4:947.